Exosomal microRNAs: potential nanotherapeutic targets for diabetic kidney disease

Nanomedicine (Lond). 2023 Oct;18(23):1669-1680. doi: 10.2217/nnm-2023-0023. Epub 2023 Nov 1.

Abstract

Diabetic kidney disease (DKD) is a primary cause for end-stage renal disease, but no specific therapeutic approaches exist. Exosomal miRNAs, a key functional cargo of nanovesicles, play crucial roles in the pathophysiological processes of DKD. Exosomal miRNAs are involved in cell-to-cell transfer of biological information, mediating nephritic inflammation, oxidative stress, apoptosis, autophagy, epithelial-mesenchymal transition and fibrosis. Circulating exosomal miRNAs derived from urine or serum might function as noninvasive prognostic biomarkers for DKD. Exosomal miRNAs from stem cells have been reported to exert beneficial effects on diabetic kidneys, which suggests that these exosomes might function as potential nanotherapy tools for treating DKD. In this review, we have summarized recent studies based on the association between exosomal miRNAs and DKD.

Keywords: diabetic kidney disease; exosomes; microRNAs; nanotherapy; stem cells.

Publication types

  • Review

MeSH terms

  • Diabetes Mellitus*
  • Diabetic Nephropathies* / drug therapy
  • Diabetic Nephropathies* / genetics
  • Epithelial-Mesenchymal Transition
  • Exosomes* / genetics
  • Humans
  • Kidney
  • MicroRNAs* / genetics

Substances

  • MicroRNAs